Aprecia Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s New Drug Application (NDA) for the first product using its proprietary ZipDose technology, a groundbreaking formulation platform that enables medicine to swiftly disperse in the patient’s mouth with a sip of water or other liquid. ZipDose products enable people to take their medications with greater ease, potentially increasing adherence and improving symptom management.

ZipDose products satisfy an unmet patient need by achieving dosage strengths that are commercially unattainable using current fast-melt technologies (orally disintegrating tablets and oral thin films). Additionally, ZipDose products are more portable than liquid formulations and have greater dosing accuracy than liquids, which are susceptible to measurement errors.

For more details, go to: https://aprecia.com/pdf/Aprecia_filing_announcement_release_FINAL_120814.pdf